Hepatic stellate cells and the reversal of fibrosis

Hepatic fibrosis is an outcome of many chronic liver diseases, such as viral and autoimmune hepatitis, and of alcohol consumption and biliary obstruction. Prolonged liver injury results in hepatocyte damage, which triggers activation of hepatic stellate cells (HSC) and recruitment of inflammatory cells into the liver. The HSC play a critical role in fibrogenesis. They produce collagen type I and secrete pro‐fibrogenic cytokines and inhibitors of matrix‐degrading enzymes (tissue inhibitor of matrix metalloproteinase), causing the production of extracellular matrix deposition over degradation. However, many clinical and experimental studies suggest that this process can be reversed, including the apoptosis of activated HSC. Thus, HSC represent an appealing target for antifibrotic therapy. This review will focus on some aspects of etiology and molecular pathogenesis of liver fibrosis and the reversal of fibrosis.

[1]  D. Brenner,et al.  Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype , 2003, Hepatology.

[2]  D. Brenner,et al.  Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis , 2001, Seminars in liver disease.

[3]  M. Varela-Rey,et al.  p38 MAPK mediates the regulation of alpha1(I) procollagen mRNA levels by TNF-alpha and TGF-beta in a cell line of rat hepatic stellate cells(1). , 2002, FEBS letters.

[4]  J. Fallowfield,et al.  Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. , 2004, Gastroenterology.

[5]  V. Paradis,et al.  Liver extracellular matrix in health and disease , 2003, The Journal of pathology.

[6]  D. Rockey,et al.  Dose‐dependent inhibition of hepatic fibrosis in mice by a TGF‐β soluble receptor: Implications for antifibrotic therapy , 2002, Hepatology.

[7]  Kazuhiro Hanazaki,et al.  Antiviral therapy for chronic hepatitis B: a review. , 2004, Current drug targets. Inflammation and allergy.

[8]  Jozsef Dudas,et al.  Interferon-gamma acts proapoptotic on hepatic stellate cells (HSC) and abrogates the antiapoptotic effect of interferon-alpha by an HSP70-dependant pathway. , 2004, European journal of cell biology.

[9]  Z. Kmieć,et al.  Cooperation of Liver Cells in Health and Disease , 2001, Advances in Anatomy Embryology and Cell Biology.

[10]  Liying Li,et al.  Antifibrogenic role of the cannabinoid receptor CB2 in the liver. , 2005, Gastroenterology.

[11]  A. Czaja,et al.  Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. , 2004, Journal of hepatology.

[12]  J. Jaffrezou,et al.  p38 MAPK mediates the regulation of α1(I) procollagen mRNA levels by TNF‐α and TGF‐β in a cell line of rat hepatic stellate cells 1 , 2002 .

[13]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[14]  T. Wynn.  Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[15]  G. Gores,et al.  Activated stellate cells express the TRAIL receptor‐2/death receptor‐5 and undergo TRAIL‐mediated apoptosis , 2003, Hepatology.

[16]  F. Oakley,et al.  The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis , 2005, Apoptosis.

[17]  J. Iredale.  Hepatic Stellate Cell Behavior during Resolution of Liver Injury , 2001, Seminars in liver disease.

[18]  T. Wynn.  Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[19]  S. Friedman,et al.  Reversal of hepatic fibrosis — Fact or fantasy? , 2006, Hepatology.

[20]  D. Brenner,et al.  Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. , 2003, Gastroenterology.

[21]  T. Wynn.  IL-13 effector functions. , 2003, Annual review of immunology.

[22]  H. Bujard,et al.  Conditional tetracycline‐regulated expression of TGF‐β1 in liver of transgenic mice leads to reversible intermediary fibrosis , 2003, Hepatology.

[23]  John P. Iredale,et al.  Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Tissue Inhibitor of Metalloproteinase-1 Is Mediated via Effects on Matrix Metalloproteinase Inhibition , 2002, The Journal of Biological Chemistry.

[24]  D. Brenner,et al.  Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. , 2001, Journal of hepatology.

[25]  G. Ramadori,et al.  Transforming growth factor β and tumor necrosis factor α inhibit both apoptosis and proliferation of activated rat hepatic stellate cells , 1999 .

[26]  M. Vidaud,et al.  Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. , 1999, Gastroenterology.

[27]  Christopher J. Parsons,et al.  Antifibrotic effects of a tissue inhibitor of metalloproteinase‐1 antibody on established liver fibrosis in rats , 2004, Hepatology.

[28]  G. Ramadori,et al.  Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. , 1999, Hepatology.

[29]  G. Ramadori,et al.  Interferon-gamma acts proapoptotic on hepatic stellate cells (HSC) and abrogates the antiapoptotic effect of interferon-alpha by an HSP70-dependant pathway. , 2005, European journal of cell biology.

[30]  J. Iredale,et al.  Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. , 2001, Gastroenterology.

[31]  R. Schwabe,et al.  Anandamide induces necrosis in primary hepatic stellate cells , 2005, Hepatology.

[32]  R. Sun,et al.  Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. , 2006, Gastroenterology.